Pentoxifylline Effective In Treating HIV-Related Skin Condition
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Pentoxifylline Effective In Treating HIV-Related Skin Condition

SCHAUMBURG, IL -- May 22, 1998 -- A drug used in the treatment of arterial disease has been found to be an effective treatment for pruritic papular eruption (PPE) of HIV-infected persons, according to a study published in the June 1988 issue of the Journal of the American Academy of Dermatology.

"Pentoxifylline is a safe and effective treatment of pruritus in HIV-infected patients," said related Brian Berman, M.D., Ph.D., at the University of Miami School of Medicine's department of dermatology and cutaneous surgery.

PPE, a severe itchy and pimple-like condition, is a common skin disease associated with HIV infection that appears on the lower extremities.

"Pruritus [itching] associated with PPE is severe, unremitting, unresponsive to traditional antipruritic medicine and often incapacitating by making patients unable to sleep," Dr. Berman explained.

Eleven of the original 12 patients completing the eight-week study were placed on a regimen of oral pentoxifylline. The degree of pruritis, both before and after therapy, was measured by a patient-reported analog scale, ranging from 0 (none) to 10 (worst experienced).

A global assessment of the number and size of PPE lesions was performed and serum TNF and triglyceride levels, as well as HIV viral load, were measured.

Results include a reduction in pruritis for 10 of the 11 patients, ranging from 22.6 percent to 87.3 percent and the global assessment of PPE lesions decreased from baseline in most patients and increased slightly in one individual.

"Future controlled studies are needed to confirm the effectiveness of this treatment," he noted.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities